Lourdes R. Freire-Fernandez

Sevilla, AN 41013, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS).

Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS).

Journal: Pharmacy (Basel, Switzerland)

Published: February 14, 2026

Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort.

Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort.

Journal: Actas dermo-sifiliograficas

Published: December 31, 2025

Validation of performance of Spanish version of PURE-4 questionnaire for early identification of psoriatic arthritis after 1 year of follow-up in patients with psoriasis.

Validation of performance of Spanish version of PURE-4 questionnaire for early identification of psoriatic arthritis after 1 year of follow-up in patients with psoriasis.

Journal: PloS one

Published: March 05, 2025

Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated With a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry.

Survival of Interleukin-17 and Interleukin-23 Inhibitors in Patients Previously Treated With a Tumor Necrosis Factor Inhibitor: Analysis of the Spanish Biobadaderm Registry.

Journal: Actas dermo-sifiliograficas

Published: May 15, 2024

Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.

Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.

Journal: Dermatologic therapy

Published: June 07, 2021

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.

Journal: Journal of the American Academy of Dermatology

Published: August 04, 2020

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.

Journal: Journal of the American Academy of Dermatology

Published: October 08, 2019

The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study.

The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study.

Journal: Journal of the American Academy of Dermatology

Published: May 22, 2019

Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review.

Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review.

Journal: Dermatology and therapy

Published: March 21, 2019

Showing 1-9 of 9

Last Updated: 09/26/2026